# LCB84

Source: https://onco.cc/drugs/lcb84/  
OnCo record `lcb84` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LCB84 is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at TROP2.

## Summary

LCB84 is a monoclonal antibody developed by LigaChem Biosciences. Its target is TROP2. ClinicalTrials.gov describes the intervention as: TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05941507, plans to enrol 300 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody directed at TROP2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of LCB84: https://clinicaltrials.gov/search?intr=LCB84
- Sponsor page: https://www.ligachembio.com

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- companies: [LigaChem Biosciences](https://onco.cc/companies/ligachem-biosciences/)
- trials: [A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors](https://onco.cc/trials/nct05941507/)

---
JSON: https://onco.cc/api/v1/entities/lcb84.json